FDA-cleared profile

FerriSmart Analysis System

Resonance Health Analysis Services Pty Ltd · MRI · FDA-cleared (510(k))

Measures R2 and liver iron concentration from MRI scans for specified systemic iron-overload and thalassemia indications.

Clinical role
Automatically analyses multi-slice spin-echo abdominal MRI to determine liver R2, converts it by calibration curve to a liver iron concentration report, and includes the analysed images for radiologist review to assist clinical diagnosis and management decisions.
Images and patients
MRI · Liver
Key limitation
Protocol-critical image quality control is required; FerriSmart and FerriScan are not interchangeable, and final management remains with the treating clinician.

Overview status: Field-derived fact summary This section is assembled from the sourced field records below; it is not a source-reviewed editorial overview.

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • Imaging and anatomyMRI · Liver
  • Workflow roleAutomatically analyses multi-slice spin-echo abdominal MRI to determine liver R2, converts it by calibration curve to a liver iron concentration report, and includes the analysed images for radiologist review to assist clinical diagnosis and management decisions.
  • Required inputMulti-slice spin-echo abdominal MRI using the specified protocol and DICOM quality-control review.
  • Output and human actionR2 and liver iron concentration in micromole and mg/g dry liver weight, with analyzed images in the report.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Measures R2 and liver iron concentration from MRI scans for specified systemic iron-overload and thalassemia indications.
  • Exact FDA submission
  • Checked 2026-09-15

Clinical-use display mirrors the exact FDA-supported purpose reconciled in this remediation finding.

Workflow role
Automatically analyses multi-slice spin-echo abdominal MRI to determine liver R2, converts it by calibration curve to a liver iron concentration report, and includes the analysed images for radiologist review to assist clinical diagnosis and management decisions.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "automatically analyses multi-slice, spin-echo MRI data sets encompassing the abdomen to determine the signal decay rate (R2) that is used to characterize iron loading in the liver, which is then transformed by a defined calibration curve" … "Liver Iron Measurement: An additional software module (algorithmic) that incorporates a calibration curve relating R2 to liver iron concentration (LIC) is added to allow production of a liver iron concentration report.". Read from the exact FDA decision document on 2026-11-14.

Required input
Multi-slice spin-echo abdominal MRI using the specified protocol and DICOM quality-control review.
  • Exact FDA submission
  • Checked 2026-09-15

FDA packet input and protocol scope.

Output and clinician action
R2 and liver iron concentration in micromole and mg/g dry liver weight, with analyzed images in the report.
  • Exact FDA submission
  • Checked 2026-09-15

FDA packet output scope.

Care setting
Individuals with confirmed or suspected systemic iron overload, transfusion-dependent thalassemia and sickle cell disease patients receiving blood transfusions, and non-transfusion-dependent thalassemia patients receiving deferasirox; the FDA document does not specify a facility type.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "measure liver iron concentration in individuals with confirmed or suspected systemic iron overload;" … "monitor liver iron burden in transfusion dependent thalassemia patients and patients with sickle cell disease receiving blood transfusions;". Read from the exact FDA decision document on 2026-11-14.

Intended users
Radiologist
  • Exact FDA submission
  • Checked 2026-09-01

Intended-user text reported in the exact-submission ACR model card.

Limitations
Protocol-critical image quality control is required; FerriSmart and FerriScan are not interchangeable, and final management remains with the treating clinician.
  • Exact FDA submission
  • Checked 2026-09-15

Exact FDA limitation boundary.

Evidence summary
Repeatability study of 60 and 971 clinical datasets; sensitivity and specificity are threshold-specific rather than one generic pair.
  • Exact FDA submission
  • Checked 2026-09-15

Submission-reported threshold-specific testing.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
Repeatability study of 60 and 971 clinical datasets; sensitivity and specificity are threshold-specific rather than one generic pair.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-15

Submission-reported threshold-specific testing.

Reported sensitivity
95%; 89%
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-13

Values reported in the exact-submission materials. Consult the linked source for endpoint, threshold, population, and confidence interval before comparison.

Reported specificity
95%; 90%
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-13

Values reported in the exact-submission materials. Consult the linked source for endpoint, threshold, population, and confidence interval before comparison.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

FerriSmart Analysis System regulatory performance study summary

  • DesignStand-Alone Performance
  • PopulationPopulation described in the exact-submission ACR model card
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K182218
  • IndependenceIndependence not established

K182218

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K182218. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-09
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Multi-slice spin-echo abdominal MRI using the specified protocol and DICOM quality-control review.

    Scope: Exact FDA submission. FDA packet input and protocol scope.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-15 · FDA K182218: FerriSmart Analysis System

  2. Routing

    Source context, not route validation: The exact-submission ACR model card explicitly references DICOM in the described input, output, or workflow; exact interfaces, versions, and local compatibility require confirmation.

    Scope: Exact FDA submission. Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-01 · FerriSmart Analysis System model card (K182218)

  3. AI processing

    Source context, not route validation: The exact FDA package describes FerriSmart as software intended to be hosted on either a cloud-based or an on-site hosted platform and used directly by the radiographer. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "The software application is a measuring medical device intended to be hosted either in a cloud- based or on site hosted platform and used directly by the radiographer.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA K182218: FerriSmart Analysis System

  4. Returned objects

    Source context, not route validation: R2 and liver iron concentration in micromole and mg/g dry liver weight, with analyzed images in the report.

    Scope: Exact FDA submission. FDA packet output scope.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-15 · FDA K182218: FerriSmart Analysis System

  5. Viewer/worklist/report

    Unresolved route: R2 and liver iron concentration in micromole and mg/g dry liver weight, with analyzed images in the report.

    Scope: Exact FDA submission. FDA packet output scope.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-15 · FDA K182218: FerriSmart Analysis System

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes FerriSmart as software intended to be hosted on either a cloud-based or an on-site hosted platform and used directly by the radiographer. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "The software application is a measuring medical device intended to be hosted either in a cloud- based or on site hosted platform and used directly by the radiographer.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
The exact-submission ACR model card explicitly references DICOM in the described input, output, or workflow; exact interfaces, versions, and local compatibility require confirmation.
  • Exact FDA submission
  • Checked 2026-09-01

Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.

Input or output interoperability

DICOM is explicitly referenced in the described input, output, or workflow.

exact submission · checked 2026-09-01

The model card does not establish every supported DICOM object, transfer method, or local interface.

Supported acquisition environment

Scanner manufacturers: All

exact submission · checked 2026-09-01

Confirm currently supported software versions, protocols, and site-specific acquisition configurations.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for FerriSmart Analysis System; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-09
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K182218
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
MRI
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-15

FDA packet MRI scope.

Anatomy
Liver
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-15

Exact FDA liver scope.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2018-11-30
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-15Last searched
26Fields reviewed
10Source classes checked
0Awaiting review PubMed leads
0Awaiting review trial leads
0Unreviewed FDA recall leads

Exact-submission ACR model-card fields were normalized under the current provenance rules; vendor and independent-study confirmation remain distinct. Exact FDA decision-summary packet reviewed on 2026-09-15. Applied FDA-supported reader facts: purpose, modality, anatomy, input, output, limitations, evidenceSummary. Facts marked unknown in the FDA packet retain any prior non-FDA source without reclassification. Candidate literature and postmarket candidates remain in their existing review state. Automated exact-name discovery found 0 PubMed and 0 ClinicalTrials.gov candidate records. Candidates require human product and version matching; zero candidates is not evidence that no studies exist. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads remain unpublished until a human confirms the exact product and tested version.

Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, fda decision summary packet, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission

    No public price or quote for the exact K182218 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-09 - Exact FDA submission

    Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.

  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-09 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-09 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

7 sources - 2 history items

Source ledger

  1. FDA K182218: FerriSmart Analysis System

    U.S. Food and Drug Administration - Published 2018-11-30 - Accessed 2026-09-09

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, purpose, input, output, limitations, evidenceSummary, deployment

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. FerriSmart Analysis System model card (K182218)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, output, limitations, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K182218

    U.S. Food and Drug Administration - Accessed 2026-09-09

    Scope: postmarketSafety

Research history

  1. K182218 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

Alternatives

Related tools to compare

FDA-cleared K253413

LiverMultiScan (v6.0)

Perspectum, Ltd.

Authorized purpose: LiverMultiScan v6.0 is MR diagnostic software for non-invasive liver-health assessment that generates, displays, and supports review of MR data and quantitative cT1, PDFF, and LIC metrics or composite images for trained healthcare-professional interpretation.

Modality
MRI
Anatomy
Liver
Decision
2026-03-09
FDA-cleared K231459

HepaFatSmart (V2.0.0)

Resonance Health Analysis Services Pty Ltd

Authorized purpose: Provide quantitative volumetric liver fat fraction, proton-density fat fraction, and steatosis grading to support clinical diagnosis and subsequent management decisions for confirmed or suspected fatty liver disease or metabolic syndromes and to aid living-donor liver-transplant assessment and screening, with results interpreted by a trained physician.

Modality
MRI
Anatomy
Liver
Decision
2023-06-20
FDA-cleared K213960

LiverMultiScan v5 (LMSv5)

Perspectum

Authorized purpose: LiverMultiScan v5 (LMSv5) is indicated for use as a magnetic resonance diagnostic device software application for noninvasive liver evaluation that enables the generation, display and review of 2D magnetic resonance medical image data and pixel maps for MR relaxation times.LMSv5 is designed to utilize DICOM 3.0 compliant magnetic resonance image datasets, acquired from compatible MRSystems, to display the internal structure of the abdomen including the liver. Other physical parameters derived from the images may also be produced.LMSv5 provides several tools, such as automated liver segmentation and region of interest (ROI) placements, to be used for the assessment of selected regions of an image. Quantitative assessment of selected regions includes the determination of triglyceride fat fraction in the liver (PDFF), T2*, LIC (Liver Iron Concentration) and iron corrected T1(cT1) measurements. These images and the physical parameters derived from the images, when interpreted by a trained clinician, yield information that may assist in diagnosis.

Modality
MRI
Anatomy
Liver
Decision
2022-09-06
FDA-cleared K213776

LiverSmart

Resonance Health Analysis Services Pty Ltd

Authorized purpose: Measures liver iron concentration for specified iron-overload and thalassemia/sickle-cell indications; assesses VLFF, PDFF, and steatosis grade for suspected or confirmed fatty liver disease; physician-interpreted results may support weight-loss monitoring and living-donor assessment.

Modality
MRI
Anatomy
Liver
Decision
2021-12-29

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history